The next 4 questions refer to the figure below. The image below represents a protein-coding gene containing 6 exons (1/2, 3, 4, 5, 6, and 7/8). This gene is transcribed and spliced and further processed in the cell to generate all the transcripts represented below, enumerated with the circled-numbers 1 through 9. The different conventions used in relation to the different components of the transcripts are shown on the left. : • 5' cap : CDS (coding sequence) Non-coding sequence (A) 250 : Poly-A tail (A) @ B(A) 250 5 b 8(A) 250 STOP 2345 a 8 (A) 250 STOP : Stop en chien ⑤ 345 b 8 (A) 250 STOP STOP : Stop enden : Trascptional start site 5 KA) (A) อ 56 KA) 250 00 8 56 Based on the data provided, answer the following questions: The blue boxes labeled 1 & 8 are likely to represent O Regulatory sequences that modulate transcription ◇ The 5' cap and the poly(A) tail, respectively O The 3' UTR and the 5' UTR, respectively O The 5' UTR and the 3' UTR, respectively O The poly(A) tail and the 5' cap, respectively O Sequences that are removed before the mature transcript is exported out of the nucleus

The next 4 questions refer to the figure below. The image below represents a protein-coding gene containing 6 exons (1/2, 3, 4, 5, 6, and 7/8). This gene is transcribed and spliced and further processed in the cell to generate all the transcripts represented below, enumerated with the circled-numbers 1 through 9. The different conventions used in relation to the different components of the transcripts are shown on the left. : • 5' cap : CDS (coding sequence) Non-coding sequence (A) 250 : Poly-A tail (A) @ B(A) 250 5 b 8(A) 250 STOP 2345 a 8 (A) 250 STOP : Stop en chien ⑤ 345 b 8 (A) 250 STOP STOP : Stop enden : Trascptional start site 5 KA) (A) อ 56 KA) 250 00 8 56 Based on the data provided, answer the following questions: The blue boxes labeled 1 & 8 are likely to represent O Regulatory sequences that modulate transcription ◇ The 5' cap and the poly(A) tail, respectively O The 3' UTR and the 5' UTR, respectively O The 5' UTR and the 3' UTR, respectively O The poly(A) tail and the 5' cap, respectively O Sequences that are removed before the mature transcript is exported out of the nucleus

Human Heredity: Principles and Issues (MindTap Course List)

11th Edition

ISBN:9781305251052

Author:Michael Cummings

Publisher:Michael Cummings

Chapter9: Gene Expression And Gene Regulation

Section: Chapter Questions

Problem 10QP: The pre-mRNA transcript and protein made by several mutant genes were examined. The results are...

See similar textbooks

Similar questions

Below is a sequence of 540 bases from a genome. What information would you use to find the beginnings and ends of open reading frames? How many open reading frames can you find in this sequence? Which open reading frame is likely to represent a protein- coding sequence, and why? Which are probably not functioning protein-coding sequences, and why? Note: for simplicitys sake, analyze only this one strand of the DNA double helix, reading from left to right, so you will only be analyzing three of the six reading frames shown in Figure 19.4.
Given the following mRNA, write the double-stranded DNA segment that served as the template. Indicate both the 5 and the 3 ends of both DNA strands. Also write out the tRNA anticodons and the amino acid sequence of the protein encoded by the mRNA message. DNA: mRNA: 5-CCGCAUGUUCAGUGGGCGUAAACACUGA-3 protein: tRNA:
IS. Alternative splicing has been estimated to occur in more than 95% of multi-exon genes. Which of the following is not an evolutionary advantage of alternative splicing? Alternative splicing increases diversity without increasing genome size Different gene isoforms can be expressed in different tissues Alternative splicing creates shorter mRNA transcripts Different gene isoforms can be expressed during different stages of development.
The following is a portion of a protein: met-trp-tyr-arg-gly-pro-thr-Various mutant forms of this protein have been recovered. Using the normal and mutant sequences, determine the DNA and mRNA sequences that code for this portion of the protein, and explain each of the mutations. a. met-trp- b. met-cys-ile-val-val-leu-gln- c. met-trp-tyr-arg-ser-pro-thr- d. met-trp-tyr-arg-gly-ala-val-ile-ser-pro-thr-
Familial retinoblastoma, a rare autosomal dominant defect, arose in a large family that had no prior history of the disease. Consider the following pedigree (the darkly colored symbols represent affected individuals): a. Circle the individual(s) in which the mutation most likely occurred. b. Is the person who is the source of the mutation affected by retinoblastoma? Justify your answer. c. Assuming that the mutant allele is fully penetrant, what is the chance that an affected individual will have an affected child?
New drugs are being developed that decrease DNA methylation and prevent the removal of acetyl groups from histone proteins. Explain how these drugs could affect gene expression to help kill tumor cells.
Given the following tRNA anticodon sequence, derive the mRNA and the DNA template strand. Also, write out the amino acid sequence of the protein encoded by this message. tRNA: UAC UCU CGA GGC mRNA: protein: How many hydrogen bonds would be present in the DNA segment?
What percentage of the DNA in the genome actually corresponds to genes? How much is actually protein-coding exons? What makes up the rest?
Pedigree Analysis Is a Basic Method in Human Genetic: What does OMIM stand for? What kinds of information are in this database?
Two genes associated with breast cancer, BRCA1 and BRCA2, were discovered in 1994 and 1995, respectively, and shortly thereafter, were patented by Myriad Genetics, a company based in Utah. Under the patents, testing for mutations in these genes could only be performed by Myriad, at costs from 300 to 3,000. Myriad also patented the process of analyzing the results of such tests, preventing anyone who obtains the sequence of their BRCA genes by other means (which itself would probably be patent infringement) from interpreting the information. The idea that genes can be patented has been a contentious issue from the beginning. Patents are not granted for products of nature, meaning that genes inside the body are not patentable, but biotech companies successfully argued that by removing a gene from the human body, purifying it, and then obtaining its DNA sequence, they created something not found in nature, and which is therefore a patentable invention. The U.S. Patent Office found the argument persuasive, but opponents argue that genes are parts of our bodies and can be identified but not invented. Biotech companies argue that without the protection offered by patents, they would have no incentive for research and development of diagnostic tests. In Europe, patents for BRCA1 and BRCA2 were revoked in 2004 because they did not meet the standards for a patent. After more than a decade of legal disputes, the patents were partially restored in 2008 on a very restricted basis. In the United States, a lawsuit, focused on the patents for the BRCA genes, was filed in May 2009. The suit challenges the basic idea that genes are patentable. In November 2009, the judge ruled that the lawsuit can proceed, and the case is moving forward. In March 2010, a federal court invalidated Myriad Genetics patent on these genes. In August 2011, the U.S. Court of Appeals reversed the lower courts decision and ruled that gene sequences isolated from cells are not a product of nature and are therefore patentable. The case went to the U.S. Supreme Court, which ordered the appeals court to reconsider the case. The Federal Appeals Court did not change its decision, and the case once again, went to the U.S. Supreme Court. A unanimous decision in June 2013 invalidated Myriads patents on the basis that isolating a gene from nature does not make it patentable. This is a landmark decision on gene patenting with widespread ramifications for the biotechnoloogy industry. Will this decision reduce the incentives for companies to invest in new diagnostic tests that would be used by cancer victims or those with serious genetic disorders?
The search for the BRCA1 breast cancer gene discussed in this chapter was widely publicized in the media (for example, Newsweek, December 6, 1993). Describe the steps taken by Mary-Claire King and her colleagues to clone this gene. How long did this process take?
Although it is well known that X-rays cause mutations, they are routinely used to diagnose medical problems, including potential tumors, broken bones, and dental cavities. Why is this done? What precautions need to be taken?